Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users

By Amendola A.   Tanzi E.   Zappa A.   Colzani D.   Boschini A.   Musher D.M.   Zanetti A.R.  

Vaccine, Vol. 20, Iss. 31, 2002-11 ,pp. : 3720-3724

Elsevier

Access to resources Recommend Favorite

Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response

By Dockrell D.H.   Poland G.A.   Steckelberg J.M.   Wollan P.C.   Strickland S.R.   Pomeroy C.  

Vaccine, Vol. 17, Iss. 22, 1999-07 ,pp. : 2779-2785

Elsevier

Access to resources Recommend Favorite

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

By Iorio A.M.   Francisci D.   Camilloni B.   Stagni G.   De Martino M.   Toneatto D.   Bugarini R.   Neri M.   Podda A.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3629-3637

Elsevier

Access to resources Recommend Favorite

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects

By Squarcione S.   Sgricia S.   Biasio L.R.   Perinetti E.  

Vaccine, Vol. 21, Iss. 11, 2003-03 ,pp. : 1268-1274

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture

By Halperin S.A.   Nestruck A.C.   Eastwood B.J.  

Vaccine, Vol. 16, Iss. 13, 1998-08 ,pp. : 1331-1335

Elsevier

Access to resources Recommend Favorite